Nexgard Combo Patent Expiration

Nexgard Combo is a drug owned by BOEHRINGER LNGELHEIM ANIMAL HEALTH USA, INC. It is protected by 7 US drug patents filed from 2026 to 2032. All patents are active. Details of Nexgard Combo’s patents and their expiration are given below.

Filter patents by

Drug Patent Number Drug Patent Expiry Status
Patent Data
US8410153 20 Jun, 2028 Active
US7964204 25 Jan, 2028 Active
US9095138 28 Dec, 2026 Active
US8231888 28 Dec, 2026 Active
US8623875 28 Dec, 2026 Active

Exclusivity Information

Nexgard Combo holds 1 exclusivity out of which 0 have expired. Its last outstanding exclusivity is set to expire in 2026. Details of Nexgard Combo's exclusivity codes and their expiration dates are given below.

Drug Exclusivity Drug Exclusivity Expiration
NCI Apr 20, 2026

About Nexgard Combo

Nexgard Combo is a drug owned by BOEHRINGER LNGELHEIM ANIMAL HEALTH USA, INC. Nexgard Combo uses Eprinomectin, Esafoxolaner, Praziquantel as the active ingredients.

Active Ingredient:

Nexgard Combo uses Eprinomectin, Esafoxolaner, Praziquantel as the active ingredients. Check out other Drugs and Companies using Eprinomectin, Esafoxolaner, Praziquantel ingredient.